

REMARKS

This communication is responsive to the Restriction Requirement dated March 31, 2009. Claims 1-26 were originally pending in the present application as indicated by the Preliminary Amendment under PCT Article 19 filed April 7, 2006. The March 31, 2009 Restriction Requirement appears to fail to consider claims 24-26 pending in the present application. Applicants request formal correction of this oversight.


Applicants elect with traverse Group I drawn to claims 1-12, 15, and 16; and SEQ ID NO:1 as the required elected single sequence for examination. Applicants respectfully submit that it would not be an undue burden for the Examiner to search, for example, subsequences of SEQ ID NO:1, such as those listed in claim 12. Claims 13, 14, and 17-23 have been withdrawn by the Amendment, and new claim 27 has been added. Claims 1-12, 15, 16 and 24-27 are therefore pending. No new matter has been added. Applicants respectfully request entry of this Amendment and Response.

CONCLUSION

Pursuant to the above remarks, reconsideration and allowance of the pending application is believed to be warranted.

Respectfully submitted,

Date: 4/12/09



Winston Ko, C.E.O.
Genervon Biopharmaceuticals LLC
Assignee of record of the entire interest